-->

Company Registry

Washburn Therapeutics Inc
Profile last edited on: 7/17/2014

Development of biologically active gels controlling inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company. Preliminary results of these gels have demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70% This technology could mean the possible prevention of burn progression through local control of inflammatory responses and overall improvement of healing outcomes.
Year Founded
2009
First SBIR Year
2010
Latest SBIR Award
2013
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6743 Wilkins Avenue
Pittsburgh, PA 15217
Multiple Locations:   
Congressional District:   18
County:   Allegheny

Public Profile

Washburn Therapeutics, Inc. is developing a new class of polymer therapeutics to treat a broad range of inflammatory conditions. Polymer therapeutics is an emerging class of drug that conjugates a known therapeutic agent to a polymer in order to provide targeted delivery. The technology was developed from Carnegie Mellon University and has been licensed exclusively by the firm. Polymer therapeutics work by using a polymer conjugation in order to localize the effects of antibody inhibitors of tumor necrosis factor- a protein known as the central mediator of inflammation. These antibodies form the basis for a $13 Billion Dollar sector of the biotechnology industry and significant safety concerns have been raised because of their powerful immunosuppressive effects. By localizing the delivery of TNF-ainhibitors, it may be possible to treat psoriasis, burns, chronic wounds, and other conditions characterized by intense, local inflammation without many of the side-effects observed through standard administering of the unconjugated drug.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Newell R Washburn -- President

SBIR firms in the news

There are no news available.